Your Health, We Care
Release date: 2026-04-10 17:53:36 Recommended: 6
In addition to the serious side effects mentioned above, XOSPATA may also cause a range of more common adverse reactions, including: abnormal liver function test results, joint or muscle pain, fatigue, fever, mouth or throat pain/ulcers, swelling of the arms or legs, rash, diarrhea, shortness of breath, nausea, cough, constipation, eye problems, headache, dizziness, low blood pressure, vomiting, and decreased urine output. If a patient experiences certain side effects, the doctor may recommend dose reduction, temporary interruption, or permanent discontinuation of treatment depending on the situation. Patients should proactively report all discomforts to their doctor and should not adjust the dose on their own. Additionally, women and men of childbearing potential must use effective contraception during treatment and for some time after stopping the medication, as XOSPATA may cause harm to the fetus.
XOSPATA may cause serious side effects, the most concerning of which is "differentiation syndrome." This is a disorder affecting blood cells that can be life‑threatening or even fatal if not treated promptly. Differentiation syndrome can appear as early as 1 day after starting treatment and can also occur within the first 3 months of therapy. If a patient experiences any of the following symptoms, they must immediately contact medical personnel or go to the emergency room: fever, cough, difficulty breathing, rash, dizziness or lightheadedness, rapid weight gain, swelling of the arms or legs, or decreased urine output. Doctors typically treat this condition with corticosteroid medications and may require the patient to be hospitalized for monitoring. Any suspicious symptoms should never be ignored.
The use of XOSPATA may also cause three other serious adverse reactions. First, posterior reversible encephalopathy syndrome (PRES), a condition affecting the brain. If a patient experiences symptoms such as seizures, headache, decreased alertness, confusion, or decreased or blurred vision, the doctor will immediately perform an evaluation. If PRES is diagnosed, XOSPATA treatment will be stopped. Second, QTc interval prolongation, an abnormality in the heart's electrical activity that can lead to life‑threatening arrhythmias. Electrocardiograms (ECGs) and monitoring of blood potassium and magnesium levels are required before treatment and periodically during treatment. If the patient feels dizzy or faints, they should inform their doctor promptly. Third, pancreatitis, manifested as severe abdominal pain that does not go away, possibly accompanied by nausea and vomiting. If any of these symptoms occur, urgent medical attention is required.
